Glyxambi

Generic name: empagliflozin and linagliptin

Used for: Type 2 diabetes · Lowering the risk of heart-related death in type 2 diabetes · 1 more

How do you pay?

How to pay the least

Cash price

$330+ for 30 tablets

Pharmacies pay about this for Glyxambi; you’d pay more.

  1. Ask your pharmacy for Glyxambi’s cash price, and one or two other pharmacies too.

No generic is sold yet.

Compare every option

Question
Brand nameGlyxambi
Authorized genericempagliflozin and linagliptin
Regular genericempagliflozin and linagliptin
What you’d pay
At least$330for 30 tablets; pharmacies pay this
Not soldThere isn’t one
Not soldNone sold yet
Same as Glyxambi?
The original
–
–

Brand nameNo maker’s card

We didn’t find a savings card or cash price from Glyxambi’s maker. Ask the pharmacy for Glyxambi’s cash price. With insurance, ask what your plan charges.

Authorized genericNot sold

There isn’t one. An authorized generic is Glyxambi itself, from the same company, sold without the brand name, and usually for less. For now Glyxambi is the only choice; ask the pharmacy for its cash price, or your plan what it charges.

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, ask the pharmacy for Glyxambi’s cash price, or your plan what it charges.

What it’s used for

What the FDA label says

GLYXAMBI is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Empagliflozin is indicated to reduce the risk of cardiovascular (CV) death in adults with type 2 diabetes mellitus and established CV disease.

Limitations of Use

  • Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.
  • Has not been studied in patients with a history of pancreatitis.
  • Not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 30 mL/min/1.73 m2.

Source: the FDA label for Glyxambi (Boehringer Ingelheim Pharmaceuticals, Inc.), January 20, 2026. Full label on DailyMed 

Good to know

Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/glyxambi/